TGR-1202 + Ublituximab — clinical trials using this drug

Public-registry trials using TGR-1202 + Ublituximab that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.

Trial	Sponsor	Condition	Phase	Sites
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials	TG Therapeutics, Inc.	Chronic Lymphocytic Leukemia	PHASE2	17

Registry history

First registered study	December 2013 — NCT02006485 (TG Therapeutics, Inc.)
Registered studies matching this name	16 all-time · 0 currently recruiting

Components TGR-1202 · Ublituximab

Source: ClinicalTrials.gov, the public trial registry.

Free site-risk snapshot for any of these trials

Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Related drugs & trials

Trialed alongside

TGR-1202

Other Chronic Lymphocytic Leukemia drugs

← Eichor home · All tracked trials · Chronic Lymphocytic Leukemia studies · Weekly briefs

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →